Regulatory News
Tuesday, May 17, 2016
BRIEF-Mallinckrodt says first patient enrolled in phase 4 trial of H.P. Acthar gel for rare cause of nephrotic syndrome
* First patient enrolled in mallinckrodt phase 4 trial of
h.p. acthar gel for rare cause of nephrotic syndrome
Source text for Eikon:
Further company coverage:
)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment